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Abstract  
Visual hallucinations are common in older people and are especially associated with 
ophthalmological and neurological disorders, including dementia and Parkinson’s disease. 
Uncertainties remain whether there is a single underlying mechanism for visual hallucinations or 
they have different disease-dependent causes. However, irrespective of mechanism, visual 
hallucinations are difficult to treat. The National Institute for Health Research (NIHR) funded a 
research programme to investigate visual hallucinations in the key and high burden areas of eye 
disease, dementia and Parkinson’s disease, culminating in a workshop to develop a unified 
framework for their clinical management. Here we summarise the evidence base, current practice 
and consensus guidelines that emerged from the workshop.  
Irrespective of clinical condition, case ascertainment strategies are required to overcome reporting 
stigma. Once hallucinations are identified, physical, cognitive and ophthalmological health should be 
reviewed, with education and self-help techniques provided. Not all hallucinations require 
intervention but for those that are clinically significant, current evidence supports pharmacological 
modification of cholinergic, GABAergic, serotonergic or dopaminergic systems, or reduction of 
cortical excitability. A broad treatment perspective is needed, including carer support. Despite their 
frequency and clinical significance, there is a paucity of randomised, placebo-controlled clinical trial 
evidence where the primary outcome is visual hallucination improvement. Key areas for future 
research include the development of valid and reliable assessment tools for use in mechanistic 
studies and clinical trials, transdiagnostic studies of shared and distinct mechanisms and when and 
how to treat visual hallucinations.     
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Introduction 
Visual hallucinations (VH) and closely-related visual perceptual symptoms (Table 1) are common in 
degenerative diseases of the brain and eye, and their prevalence varies depending on the condition 
and symptom type. The three predominant clinical contexts in which VH occur as repeated episodes 
over a prolonged course are the (i) dementias, (ii) Parkinson’s disease (PD), both in its early stages 
and after progression to PD dementia (PDD), and (iii) eye or visual pathway disease. Prevalence 
varies across different dementia subtypes with recent estimates of 55-78% in dementia with Lewy 
bodies (DLB), 32-63% in PDD, 11-17% in Alzheimer’s disease (AD) and 5-14% in vascular dementia 
[1].  In DLB, well-formed and detailed VH are a core feature and incorporated into diagnostic criteria 
[2]. The term Charles Bonnet syndrome is used to describe VH in visual impairment due to eye or 
visual pathway disease, with prevalence ranging from 15-60% depending on the degree of visual loss 
[3]. In Parkinson’s disease (PD), prevalence of VH is linked to disease duration and dopamine 
medication, with more than 80% cumulative prevalence over time [4]. 
Table 1 Glossary of terms 
• Visual hallucination - visual percept not associated with a real object. 
• Complex visual hallucination – subtype of visual hallucination whose content is a formed 
object, face, animal, figure etc.  
• Visual illusion – real object perceived incorrectly. Traditionally used to refer to errors of 
category identity (e.g. pile of cloths seen as a cat).  
• Pareidolia – specific subtype of illusion in which faces, objects etc. are perceived when 
viewing formless visual stimuli such as clouds, tree-bark, flames or in patterned visual stimuli 
such as carpets, wallpaper.  
• Metamorphopsia – a subtype of illusion used to refer to errors of spatial, temporal 
perception (e.g. seeing a real object distorted, seeing a real object persist in time or at the 
wrong spatial location).  
• Passage hallucination – animal or person passing (en passage), typically brief and in 
peripheral visual field. Characteristic of Parkinson’s disease psychosis.  
• Presence hallucination – sense of someone being close by or beside without an associated 
visual, auditory or tactile experience.  Characteristic of Parkinson’s disease psychosis.  
• Minor hallucination – collective term used in Parkinson’s disease to describe illusions, 
passage hallucinations and presence hallucinations.  
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• Multimodality hallucination – visual hallucination combined with hallucinations in other 
senses. Content in different modalities may be perceptually related (e.g. figure talking to 
you) or perceptually unrelated (disembodied voice with content unrelated to figure).  
• Pseudohallucination – In neurological literature, a hallucination with insight. In psychiatric 
literature, a hallucination in mind’s eye rather than externally projected and related to 
imagery.  
• Full insight – In context of visual hallucinations, an understanding that the experience is not 
real. Insight may be absent on the first occasion a hallucination occurs because of its 
compelling nature but with repeated instances the experience is recognised as false. 
• Partial or fluctuating insight – In context of visual hallucinations, insight is variable and 
frequently absent at the time the hallucination occurs. Insight may be restored in retrospect.  
• Secondary delusion – a false belief related to the visual hallucination (e.g. people have been 
let into the house). Secondary delusions imply impaired insight.   
 
To date, research into the mechanism and treatment of VH has focussed predominantly on these 
three clinical contexts, with the emergence of parallel, often contradictory, literature. Little 
consideration has been given to factors common to each condition or how mechanisms might 
interact when eye disease combines with dementia or PD. The National Institute for Health Research 
(NIHR) funded a 5-year research programme (SHAPED: Study of visual Hallucinations in Parkinson’s 
disease, Eye disease and Dementia) to examine VH from a trans-diagnostic perspective focussing on 
these conditions and to develop a unified framework for clinical management based on combined 
current best practice and treatment evidence. As part of this programme, we undertook an expert-
led review process of recent literature and current practice, culminating in a workshop held in April 
2018 to formulate consensus guidelines for the clinical management of VH.  
The underlying mechanism of visual hallucinations   
The workgroup highlighted two related but distinct aspects of VH mechanism that might inform 
treatment. One was what brain changes occur at the time of VH (the hallucinating state); the other 
what brain changes are associated with a susceptibility to VH (the hallucination trait). Studies of the 
hallucinating state ideally require the examination of real-time brain changes coincident with VH. 
Transient activation of the visual association cortex has been found in Charles Bonnet syndrome 
around the time of onset of VH [5], while more widespread changes have been found in PD with de-
activation of the visual association cortex and activation of the frontal cortex [6]. Differences in 
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methodology make it difficult to conclude whether this reflects a difference in the mechanism 
underlying the VH state in these disorders.  
However, most attention has been on brain changes associated with susceptibility to VH. There are 3 
mechanistic models: i) disturbed balances between top-down and bottom-up aspects of visual 
perception, ii) chronic deafferentation causing hyperexcitability to the cortical structures involved in 
vision, and iii) misattribution of internal imagery. 
The first mechanism, the Perception Attentional Dysfunction (PAD) model or related variants [7-9], 
highlights combined impairment in distributed perceptual and attentional networks leading to 
disturbed balances between top-down and bottom-up processes (or priors and sensory evidence). 
This has especially been implicated in the aetiology of hallucinations in dementia or PD and proposes 
that, in combination with poor visual perception, continuous perceptual activity is under-constrained 
by impaired attentional focus, and that the hallucinatory element of a scene is not disconfirmed by 
discrepant visual input. In contrast, the second, deafferentation-hyperexcitability, model is believed 
to underlie Charles Bonnet syndrome, and proposes hyperexcitability secondary to chronic 
functional visual deafferentation, resulting in increased spontaneous activity within the higher visual 
cortical areas leading to VH [10]. The third model, derived from psychotic disorders, is similar to PAD 
in its emphasis on unbalanced generative perception but proposes that hallucinations, whatever 
their modality, result from a failure to correctly attribute internal events as internal due to failures in 
source monitoring [11]. 
Each model is supported by a range of evidence including: cognitive / higher visual function deficits; 
functional imaging of task-related activity; resting state metabolism or blood flow; cortical / white 
matter changes; and altered structural and functional connectivity and post-mortem 
neuropathology.  The functional and structural changes differ between studies of VH, both within a 
given condition and across conditions, but may all form part of a distributed network [12, 13]. 
Pathology involving any part of the network may result in dysfunction that leads to VH, as shown for 
anatomically distinct lesion sites causing peduncular hallucinations [13].    
Post-mortem evidence has the complication that changes identified may have followed the onset of 
VH and reflect later disease progression rather than the primary cause of VH. Nevertheless, VH 
during life in patients with dementia is a strong predictor of Lewy body (LB) pathology at autopsy 
[14, 15]. In patients with VH associated with PD and DLB, LB pathology is found in the amygdala and 
para-hippocampal gyrus [16],  superior and lateral frontal cortex (Brodmann area 8/9), inferior/ 
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lateral temporal cortex (Brodmann area 20, 21), inferior parietal cortex (Brodmann area 39, 40) and 
cingulate cortex (Brodmann area 24)[regions pooled from 17, 18].  
Unlike patients with VH in the context of PD with dementia, patients with VH and relative 
preservation of cognition do not have prominent cortical or hippocampal LB involvement [19]. VH 
are also linked to higher amyloid and tau pathology in frontal, parietal and hippocampal areas [20], 
and patients with PD who go on to develop VH have CSF amyloid changes that suggest early AD 
pathology [21].  In PD without dementia, the occipital lobe is relatively free of pathology with absent 
LB and tau pathology and mild amyloid burden irrespective of whether patients experience VH [22].  
Neurotransmitter systems and VH 
In both AD and DLB, there is strong evidence for reduced cholinergic function associated with more 
frequent VH [23-26]. This is consistent with evidence from case series in PD and PDD suggesting 
improvement in VH with cholinesterase inhibitors [27-29] and improvement in VH amongst other 
neuropsychiatric symptoms in the secondary analysis of a large-scale clinical trial examining the 
effect of cholinesterase inhibitors on cognition [30].  
Neurochemical studies of CSF metabolites suggest a negative correlation between the dopamine 
metabolite homovanillic acid (HVA) and VH in a small number of LBD patients and weak negative 
correlations with aspartate and taurine in AD [31]. One suggestion is that VH susceptibility is linked 
to a specific 3,4-dihydro-xyphenylacetic acid (DOPAC)-HVA metabolic deficit, possibly as a result of a 
genetic catechol-O-methyltransferase (COMT) variation. There is also evidence of reduced striatal 
dopamine transporter (DAT) binding in patients with PD who go on to develop VH, thought to reflect 
dysfunctional fronto-striatal circuitry and altered inhibitory executive function [32-35] consistent 
with the PAD model. This may also help explain why VH in some patients with PD/PDD improve 
when their dopaminergic load is dropped or partially blocked with drugs such as clozapine or 
quetiapine. 
Post-mortem studies also highlight reductions in cholinergic and GABA activity in the absence of 
gross neuron or synapse loss, suggesting functional rather than structural changes may contribute to 
VH [36]. In PD, increased 5HT2a binding has been linked to VH in post-mortem [37] and in vivo 
neurotransmitter binding studies [38]. This may also help explain why the 5HT2a inverse agonist 
pimavanserin is effective treatment for hallucinations in PD.  
In summary, research on the mechanism of VH has largely been confined to studies within a given 
clinical condition, with a paucity of trans-diagnostic research on the wider applicability of 
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mechanisms or interactions between them. It also remains unclear whether mechanisms proposed 
for complex VH also apply to related perceptual symptoms (e.g. illusions, presence hallucinations), 
or phenomenological variants of complex VH with full, partial/fluctuating and absent insight.  
Visual hallucinations and their management 
Eye disease 
Charles Bonnet syndrome VH are associated with diseases affecting the retina, light transmission 
within the eye (e.g. cataract, corneal opacity) or visual pathways and visual cortex. They do not 
relate to a specific ocular pathology subtype [39] and can occur in monocular disease. Typical 
phenomenology includes simple hallucinations (colours and elementary shapes) geometrical 
patterns, disembodied faces and costumed figures [40]. Charles Bonnet syndrome risk increases in 
patients with severe impairment of visual acuity [3]. The frequency of VH occurrence in Charles 
Bonnet syndrome reduces over time, but more than 75% of patients will continue to experience 
hallucinations beyond 5 years after their onset [41]. Clinical impression, supported by patient 
surveys [42] is that Charles Bonnet syndrome is under-recognised with the fear of stigma reducing 
self-report. Around a third of Charles Bonnet syndrome patients have symptoms requiring clinical 
intervention beyond reassurance and education (negative outcome Charles Bonnet syndrome) [41]. 
Compared to patients with eye disease but no VH, Charles Bonnet syndrome adversely affects 
quality of life [43].  
Current practice 
For Charles Bonnet syndrome, ophthalmology services will explain symptoms, reassure and signpost 
for further support and self-help techniques, with some limited evidence from a case series that this 
may reduce VH in some people [44]. The self-help techniques aim to stop hallucinations while they 
occur and include eye-movements, changing lighting levels to increase visual input and alerting / 
distraction strategies. If clinically significant through causing distress, referral to other specialties 
may occur. A staged approach to treatment is used with a health screen and medication review and 
optimisation of vision [e.g. cataract removal, 45]. For people with VH associated with acute visual 
loss due to macular degeneration, a study of ranibizumab found improvement in 23%, with an 
association with improved visual acuity [46]. There is case-report evidence for treatment with anti-
convulsants [47, 48], cholinesterase inhibitors [49], 5HT antagonists (ondansetron) [50], SSRIs [51], 
atypical neuroleptics [52], Yi-Gan-San [a Chinese traditional medicine with multiple neurotransmitter 
effects , 53] and repetitive Transcranial Magnetic Stimulation [rTMS, 54]. However, none can be 
recommended for routine clinical use without further evidence for their efficacy. 
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Parkinson’s disease 
VH in PD form part of a progressive spectrum of symptoms (PD Psychosis) that start with illusions, 
presence hallucinations and passage hallucinations and progress to formed hallucinations, typically 
of people and animals [55]. They are a particular challenge in PD, as treatment for motor symptoms 
can trigger and worsen VH. They are associated with higher mortality [56], which may be linked to 
antipsychotic use [57], and are a stronger predictor of nursing home placement than cognitive or 
motor symptoms [58]. The stigma of mental illness may lead to under-reporting [59]. VH in PD have 
a significant negative impact on carers, with increasing carer distress as insight into the VH becomes 
impaired [59]. Compared to PD patients without VH, patients with VH have reduced quality of life 
[60].  
Current practice 
The NICE 2017 guidelines for PD [61] recommend a staged approach to treatment, typically 
undertaken within a PD service. The starting point is a review of medical or pharmacological triggers 
and a delirium screen with advice on general coping strategies [62, 63]. A reduction in PD medication 
may be necessary while monitoring for worsening motor symptoms, dopamine withdrawal 
syndrome or neuroleptic malignant syndrome. Medications should be withdrawn, starting with 
those most likely to provoke VH, i.e., anticholinergics, amantadine, and MAO-B inhibitors, followed 
by dopamine agonists and COMT inhibitors. If VH persist, the cautious withdrawal of levodopa may 
help [64, 65]. If these strategies are not effective, antipsychotic medications may be considered [66].  
Several randomised controlled trials (RCTs) have shown clozapine to be efficacious, with benefit for 
VH without worsening motor symptoms [67, 68]. Quetiapine is more widely used than clozapine, but 
there is less evidence of efficacy [69-72]. Pimavanserin, a novel antipsychotic with potent inverse 
agonist activity on the 5HT2A receptor, has emerged as a new potential therapy, with two positive 
RCTs. Meltzer et al [73] reported reduced VH, and Cummings et al. [74] reported improvements on 
psychosis scores and caregiver stress. Pimavanserin is licensed as a treatment for PD psychosis in the 
US.  Rivastigmine and donepezil are used to treat cognitive impairment in PD and may also help 
reduce VH [27-29], although to date there are no RCTs of cholinesterase inhibitors using VH as a 
primary endpoint. 
Dementia 
VH in dementia tend to be people / children, animals or objects [75]. Around 50% of patients are 
significantly distressed by their experiences, with fear and anger being the most common responses 
[76]. As core defining features of DLB, they are likely to be present at the point of diagnosis, 
contrasting with AD where VH occur in later stages of cognitive decline, 5-6 years after the onset of 
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dementia [77]. VH are associated with increased likelihood of nursing home placement [78]. As in 
PD, carer impact increases when patient insight becomes impaired [59]. 
Current practice 
VH are managed within dementia services in the wider context of neuropsychiatric symptoms. A 
staged approach is used with a physical health review, excluding delirium and other medical 
conditions that can cause VH, and medication review to reduce / stop drugs which may cause or 
exacerbate VH. Antipsychotics may have benefit [79] but potential adverse effects of severe 
antipsychotic sensitivity and mortality mean that use in LBD should be cautious. There is some 
evidence cholinesterase inhibitors reduce neuropsychiatric symptoms, including VH [30]. High dose 
cholinesterase inhibitors have been shown to reduce the frequency of VH in LBD but with increased 
side effects, needing careful titration under expert supervision [80]. A study of memantine found 
reduced hallucinations (which, although not subdivided by hallucination modality, would have 
mainly been VH) in DLB after 24 weeks treatment [81]. Transcranial magnetic stimulation and 
transcranial direct stimulation have been suggested as approaches for VH in LBD, but studies to date 
have not shown benefit [82].   
Co-morbid disease  
Studies of VH in PD or dementia typically exclude patients with eye disease so there is limited data 
on the prevalence, phenomenology or management of VH in the context of co-morbid eye disease. 
Eye disease may result in an earlier onset of VH in dementia, resulting in the misdiagnosis of AD as 
DLB [83]. Some patients presenting with Charles Bonnet syndrome to ophthalmology clinics may 
have unrecognised dementia characterised by partial or fluctuating insight into VH [84]. Case report 
evidence suggests that optimising vision may help reduce VH in dementia [85].  
Discussion  
The absence of an overarching model for VH in different disorders or evidence-based treatments 
limited the scope of the recommendations the workgroup could make. The focus of the NIHR 
programme on PD, dementia and eye disease also meant that VH in other clinical and non-clinical 
contexts were not covered (see Table 2). However, the consensus view was that where treatment 
was indicated for these other contexts, similarities in current practice across the core disorders 
covered allowed formulation of a common framework for clinical management likely to be of 
relevance to all conditions. Below we highlight key considerations, the general framework for 
managing VH and related symptoms, and areas for future research.   
12 
This is an accepted manuscript of an article published by BMJ Publishing Group in Journal of Neurology, 
Neurosurgery and Psychiatry, available online at https://jnnp.bmj.com/content/91/5/512.info. It is not the 




Table 2 Visual hallucinations in wider clinical and non-clinical context 
Condition Key features  
Parkinson’s disease Occurs throughout PD from early stage disease without 
cognitive impairment to PDD (see above). Other hallucination 
modalities can be involved in later stages.   
Charles Bonnet Syndrome Eye or visual pathway disease (see above).  
Dementia Includes AD, DLB, PDD, AD, VaD (see above). Other hallucination 
modalities can be involved.  
Co-morbid disease Eye and neurodegenerative disease combined (see above).  
Schizophrenia /  
bipolar disorder  
Visual hallucinations are less prevalent than auditory 
hallucinations in schizophrenia and other psychoses [86]. VH in 
these conditions rarely occur without auditory hallucinations 
during course of the illness and are typically interspersed with 
unimodal auditory hallucinations [86].   
Bereavement  VH of the deceased can occur as part of normal grief reaction 
but are less frequent than sensed presence of the deceased [87] 
Delirium VH are the commonest modality of hallucination in delirium [88] 
where they occur in the context of clouded consciousness, sleep 
dysregulation and affective symptoms.  
Sleep-related  Occasional VH can be normal experiences at the margins of 
sleep (hypnagogic / hypnopompic hallucinations). They may also 
present as part of a sleep-disorder (e.g. narcolepsy).  
Medication side effects PD medication can precipitate VH but the exact mechanism and 
its relation to PD neurodegeneration is unclear [35]. Medication 
with anti-muscarinic effects and opiates are particularly 
implicated in VH.   
Hallucinogen use Visual perceptual phenomena including persistent visual snow 
(see below) afterimages, palinopsia and flashback VH may 
persist after hallucinogen exposure (Hallucinogen Persisting 
Perception Disorder – HPPD) [89].  
Peduncular hallucinations Complex visual hallucinations caused by brainstem or thalamic 
lesions [90]. When caused by brainstem lesions, VH are 
associated with sleep disturbance and eye movement 
dysfunction. Hallucinations in other modalities can occur.  
Occipital / temporal seizures  Ictal phenomenology is based on location of seizure. Simple VH 
are associated with occipital foci [91]. Complex VH imply 
involvement of the temporal lobe and limbic cortex [92].   
Migraine  Teichopsia in classical migraine aura and other visual perceptual 
phenomena [93]. 
Visual snow syndrome A syndrome characterised by persistent dynamic visual noise 
(snow), palinopsia, entopic phenomena, photophobia and 
nyctalopia [94]. Associated with migraine.    
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AD = Alzheimer’s disease; DLB = Dementia with Lewy bodies; PD = Parkinson’s disease; PDD 
Parkinson’s disease dementia, VaD = vascular dementia VH= Visual hallucinations 
Case identification  
Whatever the underlying condition, help can only be provided for patients with VH if these 
symptoms have been identified by their clinical team. The workgroup identified the need to address 
continuing stigma of self-reporting symptoms perceived as indicators of mental illness or dementia. 
Evidence from eye disease that pre-emptive warning may be effective in reducing distress or 
emotional impact at VH onset [41] suggests that that low-level information about the possible future 
occurrence of VH should be provided at the point of eye disease, dementia or PD diagnosis, with 
signposting to more detailed information which can be accessed at a later stage. Systematic enquiry 
about the occurrence of VH should be part of routine follow-up to help share responsibility for 
identifying VH between the patient and care team. 
Threshold for specific treatment intervention  
The workgroup noted that VH that are not distressing for the patient or carer do not need treatment 
beyond general measures, psycho-education and help in adapting, accepting and living well with 
symptoms. Typically, this benign VH phase occurs early in the disease, highlighting the importance of 
keeping VH under review. An important factor defining the threshold at which intervention is 
required may be the transition from full insight to partial or fluctuating insight, where the patient 
responds to VH as if they are real at the time they occur, even if insight is restored after the event. 
This insight-related phenomenological distinction corresponds to that in the neurological literature 
between pseudohallucinations (defined by intact insight) and hallucinations without insight. The 
terminology is unsatisfactory as pseudohallucinations carry different implications in the psychiatric 
literature; however, the conceptual distinction between VH with insight intact in contrast to partial, 
fluctuating and absent insight states is worth revisiting as it helps mark a transition point for 
treatment need in all conditions. The workgroup also noted exceptions to the association between 
insight and treatment need, for example, intervention might be required in the presence of full, 
continuous insight where VH content is itself distressing or VH become so intrusive they limit 
function.  
Carers and VH 
Another feature of VH common to different conditions is the need to also consider their impact on 
carers. Factors mediating the increased risk of care home placement with VH are unclear but may 
include carer distress caused indirectly by VH. The consensus view was that the treatment of VH 
should extend beyond the patient to provide support and advice for the carer.  
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Consensus framework for the management of VH   
The general framework for managing VH and related symptoms is summarised in Figure 1. It begins 
before the onset of hallucinations with forewarning and pre-emptive questioning to encourage their 
reporting. Once VH are identified, a staged approach is suggested with a review of cognitive and 
ophthalmological health as well as a physical health / delirium screen. Medication should be 
reviewed, focussing on anti-muscarinic and opiate drugs and, in PD, dopaminergic therapy. Support 
including reassurance, psycho-education, normalisation (explaining VH are part of a disease and 
have a basis in brain function) and optimisation of visual functioning should be offered. This should 
be person-centred, identifying the particular triggers and settings that increase the risk of VH and 
avoiding these situations by planning alternative meaningful and rewarding activities.  
VH that become clinically significant by causing distress to the patient or their carers require further 
intervention. Given limitations in both understanding of the underlying mechanism(s) of VH 
susceptibility or the neurophysiological changes coincident with VH and the clinical trial evidence 
base, the workgroup were unable to make definitive medication recommendations. There is a 
theoretical basis for pharmacological interventions targeting cholinergic, GABAergic, serotonergic or 
dopaminergic systems and for reducing cortical excitability through non-invasive stimulation or 
anticonvulsant medication. Treatment might aim to reverse long-term changes associated with VH 
susceptibility or to reduce the frequency or duration of transient changes co-incident with VH.  
Future directions 
The working group noted an important methodological challenge for clinical trials or mechanistic 
studies is the lack of accepted, validated, rating scales for VH or related symptoms. There is a clear 
need to develop better metrics which extend beyond retrospective collection of questionnaire or 
scale data to real-world collection of VH as they occur using, for example, new mobile technology or 
real-time functional data through developments in EEG telemetry. Measures of VH susceptibility are 
also required, such as pareidolia tests developed for DLB [95, 96]. Given the importance of insight 
and its continuity at the decision point for specific intervention, better measures of insight which are 
sensitive to partial or fluctuating states are required, as well as studies of the cognitive context in 
which insight becomes impaired, for example, generalised cognitive decline or decline in specific 
cognitive functions such as self-monitoring or symptom-awareness [97]. 
For clinical trials, the workgroup highlighted the lack of standardisation of VH-related outcome 
measures and the need for trials taking a trans-diagnostic, mechanism-based perspective to 
complement evidence from the traditional condition-specific trials. It remains to be established 
whether a single treatment approach will be effective in all conditions or whether different 
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treatments will be required with further studies needed of the underlying mechanism of VH from a 
trans-diagnostic perspective and the role of dysfunction in distributed brain networks.   Clinical trials 
for non-pharmacological approaches are also required, in particular the role of psychological 
therapies such as re-scripting, imagery transformation, desensitisation, CBT targeting patient-carer 
dyads and non-invasive brain stimulation. Both medication and non-pharmacological trials might 
target longer-term susceptibility or transient changes, either separately or in combination.  
Conclusions 
Although the clinical importance of VH and related symptoms has long been recognised, the 
evidence-base for their mechanism or treatment is limited and focuses on single conditions. A wider 
perspective is required, highlighting key similarities and differences between conditions and taking 
into account brain changes conferring susceptibility to such symptoms as well as those co-incident 
with their occurrence. In advance of such developments, the workgroup concluded that treatment 
of VH, irrespective of their clinical context, would benefit from a common management framework 
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Figure legend 
Figure 1. The consensus framework for the management of visual hallucinations in different 
conditions. Recommendations not supported by meta-analysis are indicated in white. Orange boxes 
indicate hallucination characteristics and therapeutic targets.  
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